Alvotech/$ALVO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Alvotech
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
- Ticker
- $ALVO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,279
- Headquarters
- Luxembourg, Luxembourg
- Website
- www.alvotech.com
Alvotech Metrics
BasicAdvanced
$1.7B
-
-$0.61
0.18
-
Price and volume
Market cap
$1.7B
Beta
0.18
52-week high
$7.81
52-week low
$2.94
Average daily volume
989K
Financial strength
Current ratio
1.646
Quick ratio
0.793
Long term debt to equity
-7.301
Total debt to equity
-7.582
Interest coverage (TTM)
0.33%
Profitability
EBITDA (TTM)
75.733
Gross margin (TTM)
60.66%
Net profit margin (TTM)
-36.31%
Operating margin (TTM)
10.54%
Effective tax rate (TTM)
-458.44%
Revenue per employee (TTM)
$390,000
Management effectiveness
Return on assets (TTM)
2.19%
Return on equity (TTM)
98.46%
Valuation
Price to revenue (TTM)
2.777
Price to book
-8.67
Price to tangible book (TTM)
-4.79
Price to free cash flow (TTM)
-4.114
Free cash flow yield (TTM)
-24.31%
Free cash flow per share (TTM)
-1.13
Growth
Revenue change (TTM)
-12.07%
Earnings per share change (TTM)
-382.78%
3-year revenue growth (CAGR)
96.63%
3-year earnings per share growth (CAGR)
-31.52%
What the Analysts think about Alvotech
Analyst ratings (Buy, Hold, Sell) for Alvotech stock.
Analyst projections of the future price of Alvotech stock.
Bulls say / Bears say
Alvotech now has five biosimilars contributing to product revenue, broadening its commercial base beyond its earlier Humira and Stelara franchises. New product launches across Europe and Japan give it more avenues for growth. (Alvotech)
First-half adjusted revenue fell 31% year on year as manufacturing improvements constrained output and product availability. The recovery depends on the production ramp translating into stronger sales in the second half. (Alvotech)
Alvotech carries about $1.31 billion of borrowings and reported $80.2 million of operating cash outflow in the first half. Heavy interest costs and continued investment could leave it reliant on further financing if commercial growth does not generate enough cash. (StockTitan)
U.S. launches are still contingent on regulatory decisions: the FDA previously returned applications for manufacturing deficiencies, and the resubmitted applications remain subject to individual review. Further concerns could delay approvals and expected commercial growth. (StockTitan, Alvotech)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2026.
Alvotech Financial Performance
Revenues and expenses
Alvotech Earnings Performance
Company profitability
Upcoming events
No upcoming events
Alvotech News
AllArticlesVideos
Funds containing Alvotech
Fund name | Fund size | $ALVO weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.11% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.11% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.